The COVID-19 pandemic brought many challenges to sponsors and regulatory bodies wishing to develop vaccines and/or treatments for COVID-19. It was imperative to work at top speed and the standard of care was changing rapidly. FDA has issued Emergency Use Authorization (EUA) for both vaccines and treatments.
Join us for an extremely relevant session at the DIA/FDA Biostatistics Industry and Regulatory Forum, April 14-16, which will include case studies that highlight particular issues of COVID-19 clinical development and how they were dealt with by sponsors and FDA. Speakers will also discuss the statistical issues and solutions to handle the unprecedented uncertainty and changing dynamics.
Early Bird Rates are in effect through February 18. Don't miss out on this exclusive event!
Plus: Never miss a moment at the forum as all session recordings will be available to you for four months after the forum concludes!
--------------------
http://track.diaglobal.org/n0St0Y301uO80JV0fy01sfa